Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Global funding cuts, including those made by the Trump administration, are set to increase cases of HIV in Africa, research suggests.

Niagen has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital to treat Parkinson's disease.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma, ...

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.